Find Cabozantinib manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Related ProductsRelated Products

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 1140909-48-3, Cabozantinib malate, Cabozantinib (s)-malate, Cabometyx, Cabozantinib malate (xl184), Xl184
Molecular Formula
C32H30FN3O10
Molecular Weight
635.6  g/mol
InChI Key
HFCFMRYTXDINDK-WNQIDUERSA-N
FDA UNII
DR7ST46X58

Cabozantinib
Cabozantinib S-malate is the s-malate salt form of cabozantinib, an orally bioavailable, small molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Cabozantinib strongly binds to and inhibits several RTKs, which are often overexpressed in a variety of cancer cell types, including hepatocyte growth factor receptor (MET), RET (rearranged during transfection), vascular endothelial growth factor receptor types 1 (VEGFR-1), 2 (VEGFR-2), and 3 (VEGFR-3), mast/stem cell growth factor (KIT), FMS-like tyrosine kinase 3 (FLT-3), TIE-2 (TEK tyrosine kinase, endothelial), tropomyosin-related kinase B (TRKB) and AXL. This may result in an inhibition of both tumor growth and angiogenesis, and eventually lead to tumor regression.
1 2D Structure

Cabozantinib

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
1-N-[4-(6,7-dimethoxyquinolin-4-yl)oxyphenyl]-1-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide;(2S)-2-hydroxybutanedioic acid
2.1.2 InChI
InChI=1S/C28H24FN3O5.C4H6O5/c1-35-24-15-21-22(16-25(24)36-2)30-14-11-23(21)37-20-9-7-19(8-10-20)32-27(34)28(12-13-28)26(33)31-18-5-3-17(29)4-6-18;5-2(4(8)9)1-3(6)7/h3-11,14-16H,12-13H2,1-2H3,(H,31,33)(H,32,34);2,5H,1H2,(H,6,7)(H,8,9)/t;2-/m.0/s1
2.1.3 InChI Key
HFCFMRYTXDINDK-WNQIDUERSA-N
2.1.4 Canonical SMILES
COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O
2.1.5 Isomeric SMILES
COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C([C@@H](C(=O)O)O)C(=O)O
2.2 Other Identifiers
2.2.1 UNII
DR7ST46X58
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Bms 907351

2. Bms-907351

3. Bms907351

4. Cabozantinib

5. Cometriq

6. Xl 184

7. Xl-184

8. Xl184 Cpd

2.3.2 Depositor-Supplied Synonyms

1. 1140909-48-3

2. Cabozantinib Malate

3. Cabozantinib (s)-malate

4. Cabometyx

5. Cabozantinib Malate (xl184)

6. Xl184

7. Cabozantinib (s-malate)

8. Cometriq

9. Cabozantinib S-malate [usan]

10. Dr7st46x58

11. Bms907351

12. Chebi:72319

13. N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)-n-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide (s)-2-hydroxysuccinate

14. Cabometyx (tn)

15. Cometriq (tn)

16. Cabozantinib Malate (jan)

17. 1-n-[4-(6,7-dimethoxyquinolin-4-yl)oxyphenyl]-1-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide;(2s)-2-hydroxybutanedioic Acid

18. Cabozantinib S-malate (usan)

19. Cabozantinib Malate [jan]

20. Unii-dr7st46x58

21. Butanedioic Acid, 2-hydroxy-, (2s)-, Compd. With N-(4-((6,7-dimethoxy-4-quinolinyl)oxy)phenyl)-n'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide (1:1)

22. Butanedioic Acid, 2-hydroxy-, (2s)-, Compd. With N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-n'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide (1:1)

23. Xl184 Malate

24. Cabozantinib L-malate

25. Bms907351 Malate

26. Xl184(cabozantinib Malate)

27. Mls006010951

28. Chembl2103868

29. Dtxsid60915949

30. Ex-a2819

31. Mfcd20923480

32. S4001

33. 1140909-48-3 (malate)

34. Akos025401945

35. Cabozantinib S-malate [who-dd]

36. Ccg-270301

37. Cs-0201

38. (2s)-2-hydroxybutanedioic Acid Compd. With N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-n'-(4-fluor

39. (2s)-2-hydroxybutanedioic Acid Compd. With N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-n'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide (1:1)

40. Ac-27471

41. As-75255

42. Hy-12044

43. Smr004702755

44. Cabozantinib S-malate [orange Book]

45. Sw218093-2

46. D10095

47. Q27139901

48. (2s)-2-hydroxybutanedioic Acid Compd. With N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-n'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide

49. (2s)-2-hydroxybutanedioic Acid Compd. With N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-n-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide (1:1)

50. (2s)-2-hydroxybutanedioic Acid; N'1-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n1-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide

51. 1,1-cyclopropanedicarboxamide, N'-(4-((6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-n-(4- Fluorophenyl)- Mono((2s)-2-hydroxybutanedioate)

52. Cyclopropane-1,1-dicarboxylic Acid [4-(6,7-dimethoxy-quinoline-4-yloxy)-phenyl]-amide(4-fluoro-phenyl)-amide, (s) Malate Salt

53. N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide Mono((2s)-2-hydroxybutanedioate)

54. N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-n-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide (s)-2-hydroxysuccinate

55. N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide (2s)-2-hydroxybutanedioate

2.4 Create Date
2008-12-22
3 Chemical and Physical Properties
Molecular Weight 635.6 g/mol
Molecular Formula C32H30FN3O10
Hydrogen Bond Donor Count5
Hydrogen Bond Acceptor Count12
Rotatable Bond Count11
Exact Mass635.19152232 g/mol
Monoisotopic Mass635.19152232 g/mol
Topological Polar Surface Area194 Ų
Heavy Atom Count46
Formal Charge0
Complexity924
Isotope Atom Count0
Defined Atom Stereocenter Count1
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count2
4 Drug and Medication Information
4.1 Drug Indication

* Renal Cell Carcinoma (RCC):

Cabometyx is indicated as monotherapy for the treatment of advanced renal cell carcinoma (RCC):

- in treatment-nave adults with intermediate or poor risk,

- in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy.

Cabometyx, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults.

* Hepatocellular Carcinoma (HCC):

Cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (HCC) in adults who have previously been treated with sorafenib.


5 Pharmacology and Biochemistry
5.1 ATC Code

L01EX07


API SUPPLIERS

read-more
read-more

01

Granules India Limited

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothGranules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

Flag India
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Granules India

02

Sichuan Elixir Pharmaceuticals

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Saudi International Expo
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothSichuan Elixir Pharmaceutical, a manufacturer of small molecule APIs & a CMO/CDMO service provider for anti-tumor characteristic APIs..

Flag China
Digital Content Digital Content
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Sichuan Elixir Pharmaceuticals

03

ChemWerth Inc

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Saudi International Expo
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

Flag U.S.A
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Chemwerth Compnay Banner

04

Transo-Pharm USA LLC

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Saudi International Expo
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothTransoPharm USA works in the Sourcing and Management of Active Pharmaceutical Ingredients.

Flag U.S.A
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Transo Pharm USA Company Banner

05

LGM Pharma

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothLGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

Flag U.S.A
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
LGM Pharma CB

06

Fermion Oy

Finland

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothWith Fermion, start the journey of your innovative API.

Flag Finland
Digital Content Digital Content
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
fermion

07

Dr. Reddy's Laboratories

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Flag India
Digital Content Digital Content
USDMF arrow-down CEP/COS JDMF EU-WC NDC arrow-down KDMF VMF Others AUDIT
Dr Reddy Company Banner

08

Tagoor Laboratories

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothTagoor's product development expertise, backed by our comprehensive understanding of the processes, helps us offer high-quality APIs.

Flag India
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Tagoor Laboratories

09

Sichuan Elixir Pharmaceuticals

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Saudi International Expo
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothSichuan Elixir Pharmaceutical, a manufacturer of small molecule APIs & a CMO/CDMO service provider for anti-tumor characteristic APIs..

Flag China
Digital Content Digital Content
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Sichuan Elixir Pharmaceuticals

10

Dr. Reddy's Laboratories

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Flag India
Digital Content Digital Content
USDMF arrow-down CEP/COS JDMF EU-WC NDC arrow-down KDMF VMF Others AUDIT
Dr Reddy Company Banner
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

USDMF

read-more
read-more

01

SupplySide West 2024
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothSichuan Elixir Pharmaceutical, a manufacturer of small molecule APIs & a CMO/CDMO service provider for anti-tumor characteristic APIs..

Flag China
Digital Content Digital Content

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 39785

Submission : 2024-03-26

Status : Active

Type : II

Sichuan Elixir Pharmaceuticals

02

SupplySide West 2024
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothSichuan Elixir Pharmaceutical, a manufacturer of small molecule APIs & a CMO/CDMO service provider for anti-tumor characteristic APIs..

Flag China
Digital Content Digital Content

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 39757

Submission : 2024-03-22

Status : Active

Type : II

Sichuan Elixir Pharmaceuticals

03

Fermion Oy

Finland
arrow
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothWith Fermion, start the journey of your innovative API.

Flag Finland
Digital Content Digital Content

GDUFA

DMF Review : Complete

Rev. Date : 2020-04-17

Pay. Date : 2020-02-27

DMF Number : 34437

Submission : 2020-02-25

Status : Active

Type : II

fermion

04

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Flag India
Digital Content Digital Content

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 39274

Submission : 2023-12-29

Status : Active

Type : II

Dr Reddy Company Banner

05

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Flag India
Digital Content Digital Content

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 39141

Submission : 2023-12-01

Status : Active

Type : II

Dr Reddy Company Banner

06

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Flag India
Digital Content Digital Content

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 38207

Submission : 2023-03-31

Status : Active

Type : II

Dr Reddy Company Banner

07

Biocon Ltd

India

USDMF

arrow
SupplySide West 2024
Not Confirmed

07

Biocon Ltd

India
arrow
SupplySide West 2024
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2023-12-06

Pay. Date : 2023-03-08

DMF Number : 38057

Submission : 2023-09-28

Status : Active

Type : II

blank

08

SupplySide West 2024
Not Confirmed

08

SupplySide West 2024
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2017-06-08

Pay. Date : 2017-05-22

DMF Number : 31522

Submission : 2017-03-30

Status : Active

Type : II

blank

09

SupplySide West 2024
Not Confirmed

09

SupplySide West 2024
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2019-06-25

Pay. Date : 2019-04-22

DMF Number : 33137

Submission : 2018-09-01

Status : Active

Type : II

blank

10

Natco Pharma Ltd

India

USDMF

arrow
SupplySide West 2024
Not Confirmed

10

SupplySide West 2024
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2022-03-23

Pay. Date : 2022-02-28

DMF Number : 36509

Submission : 2022-02-28

Status : Active

Type : II

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

EU WC

read-more
read-more

01

World Vaccine Congress
Not Confirmed
arrow
arrow
World Vaccine Congress
Not Confirmed

Cabozantinib (s)-Maleate IH

Date of Issue : 2022-09-02

Valid Till : 2025-05-05

Written Confirmation Number : WC-0349

Address of the Firm : MIs. MSN Laboratories Private Limited, Unit-II, sv. No, 50, Kardanur (Village), ...

blank

02

World Vaccine Congress
Not Confirmed
arrow
arrow
World Vaccine Congress
Not Confirmed

Cabozantinib malate IH

Date of Issue : 2019-08-05

Valid Till : 2022-05-05

Written Confirmation Number : WC-0349A3

Address of the Firm : Unit-||, Sy. No. 50, Kardanur Village, Patti/Post Patancheru Mandal,Medak Distri...

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

NDC API

read-more
read-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Flag India
Digital Content Digital Content

CABOZANTINIB

NDC Package Code : 71796-059

Start Marketing Date : 2023-03-31

End Marketing Date : 2024-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

Dr Reddy Company Banner

02

SupplySide West 2024
Not Confirmed
arrow
arrow
SupplySide West 2024
Not Confirmed

CABOZANTINIB S-MALATE

NDC Package Code : 48957-0121

Start Marketing Date : 2021-02-26

End Marketing Date : 2024-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

03

SupplySide West 2024
Not Confirmed
arrow
arrow
SupplySide West 2024
Not Confirmed

CABOZANTINIB S-MALATE

NDC Package Code : 65727-091

Start Marketing Date : 2023-07-24

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

04

SupplySide West 2024
Not Confirmed
arrow
arrow
SupplySide West 2024
Not Confirmed

CABOZANTINIB S-MALATE

NDC Package Code : 54893-0078

Start Marketing Date : 2018-07-20

End Marketing Date : 2024-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

05

SupplySide West 2024
Not Confirmed
arrow
arrow
SupplySide West 2024
Not Confirmed

CABOZANTINIB S-MALATE

NDC Package Code : 54893-0058

Start Marketing Date : 2017-02-06

End Marketing Date : 2024-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

06

SupplySide West 2024
Not Confirmed
arrow
arrow
SupplySide West 2024
Not Confirmed

CABOZANTINIB S-MALATE

NDC Package Code : 55679-116

Start Marketing Date : 2012-11-15

End Marketing Date : 2024-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

07

SupplySide West 2024
Not Confirmed
arrow
arrow
SupplySide West 2024
Not Confirmed

CABOZANTINIB S-MALATE

NDC Package Code : 59057-013

Start Marketing Date : 2022-08-31

End Marketing Date : 2024-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

08

SupplySide West 2024
Not Confirmed
arrow
arrow
SupplySide West 2024
Not Confirmed

CABOZANTINIB

NDC Package Code : 59057-018

Start Marketing Date : 2024-09-02

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

09

STERLING SPA

Italy
SupplySide West 2024
Not Confirmed
arrow

STERLING SPA

Italy
arrow
SupplySide West 2024
Not Confirmed

CABOZANTINIB

NDC Package Code : 64918-1924

Start Marketing Date : 2023-05-12

End Marketing Date : 2024-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank

10

Valary Lab Private Limited

Country
SupplySide West 2024
Not Confirmed
arrow

Valary Lab Private Limited

Country
arrow
SupplySide West 2024
Not Confirmed

CABOZANTINIB S-MALATE

NDC Package Code : 81955-0021

Start Marketing Date : 2012-11-29

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (1kg/kg)

Marketing Category : BULK INGREDIENT

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

API Reference Price

read-more
read-more
[{"dataSource":"API Export","activeIngredients":"","year":"2021","qtr":"Q4","strtotime":1638383400,"product":"CABOZANTINIB (S)-MALATE","address":"MSN HOUSE, PLOT NO. C-24,INDUSTRIAL HYDERABAD","city":"HYDERABAD","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"SEOUL","customer":"BORYUNG PHARMACEUTICAL CO., LTD","customerCountry":"KOREA, REPUBLIC OF","quantity":"2.50","actualQuantity":"2.5","unit":"KGS","unitRateFc":"34000","totalValueFC":"82716.7","currency":"USD","unitRateINR":2495600,"date":"02-Dec-2021","totalValueINR":"6239000","totalValueInUsd":"82716.7","indian_port":"HYDERABAD AIR","hs_no":"29337990","bill_no":"6452083","productDescription":"API","marketType":"REGULATED MARKET","country":"KOREA,REPUBLIC OF","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"MSN HOUSE, PLOT NO. C-24,INDUSTRIAL HYDERABAD, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q1","strtotime":1642012200,"product":"CABOZANTINIB (S)-MALATE (TAX INV NO:1905","address":"MSN HOUSE, PLOT NO. C-24,INDUSTRIAL HYDERABAD","city":"HYDERABAD","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"HONG KONG","customer":"BIOBETTA PHARMACEUTICALS SHANGHAI","customerCountry":"HONG KONG","quantity":"4.50","actualQuantity":"4.5","unit":"KGS","unitRateFc":"18000","totalValueFC":"79819.1","currency":"USD","unitRateINR":1321333.3333333333,"date":"13-Jan-2022","totalValueINR":"5946000","totalValueInUsd":"79819.1","indian_port":"HYDERABAD AIR","hs_no":"29337990","bill_no":"7464169","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"HONG KONG","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"MSN HOUSE, PLOT NO. C-24,INDUSTRIAL HYDERABAD, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1690828200,"product":"CABOZANTINIB (S) MALATE","address":"MSN HOUSE PLOT NO. C-24INDUSTRI AL ESTATE SANATH NAGAR","city":"Hyderabad","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"NA","customer":"TO THE ORDER OF","customerCountry":"CHINA","quantity":"4.50","actualQuantity":"4.5","unit":"KGS","unitRateFc":"15955.1","totalValueFC":"70986.5","currency":"USD","unitRateINR":1306724.1459999999,"date":"01-Aug-2023","totalValueINR":"5880258.657","totalValueInUsd":"70986.5","indian_port":"HYDERABAD ICD","hs_no":"29337990","bill_no":"0","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD ICD","supplierAddress":"MSN HOUSE PLOT NO. C-24INDUSTRI AL ESTATE SANATH NAGAR, Hyderabad","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1691001000,"product":"CABOZANTINIB (S) MALATE","address":"MSN HOUSE PLOT NO. C-24INDUSTRI AL ESTATE SANATH NAGAR","city":"Hyderabad","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"NA","customer":"TO THE ORDER OF","customerCountry":"CHINA","quantity":"4.50","actualQuantity":"4.5","unit":"KGS","unitRateFc":"15955.1","totalValueFC":"70986.5","currency":"USD","unitRateINR":1306724.1459999999,"date":"03-Aug-2023","totalValueINR":"5880258.657","totalValueInUsd":"70986.5","indian_port":"HYDERABAD ICD","hs_no":"29337990","bill_no":"0","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD ICD","supplierAddress":"MSN HOUSE PLOT NO. C-24INDUSTRI AL ESTATE SANATH NAGAR, Hyderabad","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q2","strtotime":1717698600,"product":"CABOZANTINIB (S)-MALATE (FORM-S)","address":"MSN HOUSE, PLOT NO. C-24,","city":"HYDERABAD. AP","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"SEOUL - INCHEON INT\\'","customer":"BORYUNG CORPORATION","customerCountry":"REPUBLIC OF KOREA","quantity":"1.00","actualQuantity":"1","unit":"KGS","unitRateFc":"25000","totalValueFC":"24736.6","currency":"USD","unitRateINR":2065000,"date":"07-Jun-2024","totalValueINR":"2065000","totalValueInUsd":"24736.6","indian_port":"Hyderabad Air","hs_no":"29337990","bill_no":"1503900","productDescription":"API","marketType":"REGULATED MARKET","country":"REPUBLIC OF KOREA","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"MSN HOUSE, PLOT NO. C-24,, HYDERABAD. AP","customerAddress":""}]
02-Dec-2021
07-Jun-2024
KGS
overview
Loading...

Average Price (USD/KGS)

Number of Transactions

Total Quantity (KGS)

Total Value (USD)

Quantity (KGS) & Unit rate (USD/KGS) over time

API Imports and Exports

Importing Country Total Quantity
(KGS)
Average Price
(USD/KGS)
Number of Transactions

Upgrade, download data, analyse, strategize, subscribe with us contact

Drugs in Development

read-more
read-more

Details:

Cabometyx (cabozantinib S-malate) is a TK inhibitor which is being investigated in advanced pancreatic neuroendocrine tumors.


Lead Product(s): Cabozantinib

Therapeutic Area: Oncology Brand Name: Cabometyx

Study Phase: Phase IIIProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 16, 2024

blank

01

Ipsen

France
arrow
SupplySide West 2024
Not Confirmed

Ipsen

France
arrow
SupplySide West 2024
Not Confirmed

Details : Cabometyx (cabozantinib S-malate) is a TK inhibitor which is being investigated in advanced pancreatic neuroendocrine tumors.

Brand Name : Cabometyx

Molecule Type : Small molecule

Upfront Cash : Not Applicable

September 16, 2024

blank

Details:

Cabometyx (Cabozantinib) tablet is a TK inhibitor, being investigated in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer.


Lead Product(s): Cabozantinib,Atezolizumab

Therapeutic Area: Oncology Brand Name: Cabometyx

Study Phase: Phase IIIProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 15, 2024

blank

02

Ipsen

France
arrow
SupplySide West 2024
Not Confirmed

Ipsen

France
arrow
SupplySide West 2024
Not Confirmed

Details : Cabometyx (Cabozantinib) tablet is a TK inhibitor, being investigated in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer.

Brand Name : Cabometyx

Molecule Type : Small molecule

Upfront Cash : Not Applicable

September 15, 2024

blank

Details:

Cabometyx (cabozantinib S-malate) is a TK inhibitor which is being investigated for the treatment of patients with advanced pancreatic neuroendocrine tumors.


Lead Product(s): Cabozantinib

Therapeutic Area: Oncology Brand Name: Cabometyx

Study Phase: Phase IIIProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 06, 2024

blank

03

Exelixis

U.S.A
arrow
SupplySide West 2024
Not Confirmed

Exelixis

U.S.A
arrow
SupplySide West 2024
Not Confirmed

Details : Cabometyx (cabozantinib S-malate) is a TK inhibitor which is being investigated for the treatment of patients with advanced pancreatic neuroendocrine tumors.

Brand Name : Cabometyx

Molecule Type : Small molecule

Upfront Cash : Not Applicable

August 06, 2024

blank

Details:

The collaboration with Exelixis for the development of Cabometyx (cabozantinib S-malate) in advanced pancreatic neuroendocrine tumors and advanced extra-pancreatic neuroendocrine tumor.


Lead Product(s): Cabozantinib

Therapeutic Area: Oncology Brand Name: Cabometyx

Study Phase: Phase IIIProduct Type: Small molecule

Sponsor: Exelixis

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration July 02, 2024

blank

04

Ipsen

France
arrow
SupplySide West 2024
Not Confirmed

Ipsen

France
arrow
SupplySide West 2024
Not Confirmed

Details : The collaboration with Exelixis for the development of Cabometyx (cabozantinib S-malate) in advanced pancreatic neuroendocrine tumors and advanced extra-pancreatic neuroendocrine tumor.

Brand Name : Cabometyx

Molecule Type : Small molecule

Upfront Cash : Undisclosed

July 02, 2024

blank

Details:

Kura's lead product KO-2806, which is a Ftase inhibitor got dosing of the first patient in Phase I clinical trial studies in combination with cabozantinib for the treatment of Renal Cell Carcinoma.


Lead Product(s): KO-2806,Cabozantinib

Therapeutic Area: Oncology Brand Name: KO-2806

Study Phase: Phase IProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 06, 2024

blank

05

SupplySide West 2024
Not Confirmed
SupplySide West 2024
Not Confirmed

Lead Product(s) : KO-2806,Cabozantinib

Therapeutic Area : Oncology

Highest Development Status : Phase I

Partner/Sponsor/Collaborator : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

Details : Kura's lead product KO-2806, which is a Ftase inhibitor got dosing of the first patient in Phase I clinical trial studies in combination with cabozantinib for the treatment of Renal Cell Carcinoma.

Brand Name : KO-2806

Molecule Type : Small molecule

Upfront Cash : Not Applicable

March 06, 2024

blank

Details:

Opdivo (nivolumab) is a programmed death-1 (PD-1) immune checkpoint inhibitor. It is being evaluated in combination with Cabometyx (cabozantinib) for first-line advanced renal cell carcinoma.


Lead Product(s): Nivolumab,Cabozantinib

Therapeutic Area: Oncology Brand Name: Opdivo

Study Phase: ApprovedProduct Type: Large molecule

Sponsor: Exelixis

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 22, 2024

blank

06

SupplySide West 2024
Not Confirmed
SupplySide West 2024
Not Confirmed

Details : Opdivo (nivolumab) is a programmed death-1 (PD-1) immune checkpoint inhibitor. It is being evaluated in combination with Cabometyx (cabozantinib) for first-line advanced renal cell carcinoma.

Brand Name : Opdivo

Molecule Type : Large molecule

Upfront Cash : Not Applicable

January 22, 2024

blank

Details:

KO-2806 is farnesyl transferase inhibitor which demonstrated in combination with KRASG12C inhibitors to drive tumor regressions and durable responses in KRASG12C-mutantion non-small cell lung cancer (NSCLC).


Lead Product(s): KO-2806,Cabozantinib

Therapeutic Area: Oncology Brand Name: KO-2806

Study Phase: Phase IProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 19, 2023

blank

07

SupplySide West 2024
Not Confirmed
SupplySide West 2024
Not Confirmed

Lead Product(s) : KO-2806,Cabozantinib

Therapeutic Area : Oncology

Highest Development Status : Phase I

Partner/Sponsor/Collaborator : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

Details : KO-2806 is farnesyl transferase inhibitor which demonstrated in combination with KRASG12C inhibitors to drive tumor regressions and durable responses in KRASG12C-mutantion non-small cell lung cancer (NSCLC).

Brand Name : KO-2806

Molecule Type : Small molecule

Upfront Cash : Not Applicable

October 19, 2023

blank

Details:

KO-2806 is farnesyl transferase inhibitor which demonstrated in combination with KRASG12C inhibitors to drive tumor regressions and durable responses in KRASG12C-mutant non-small cell lung cancer (NSCLC).


Lead Product(s): KO-2806,Cabozantinib

Therapeutic Area: Oncology Brand Name: KO-2806

Study Phase: Phase IProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 28, 2023

blank

08

SupplySide West 2024
Not Confirmed
SupplySide West 2024
Not Confirmed

Lead Product(s) : KO-2806,Cabozantinib

Therapeutic Area : Oncology

Highest Development Status : Phase I

Partner/Sponsor/Collaborator : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

Details : KO-2806 is farnesyl transferase inhibitor which demonstrated in combination with KRASG12C inhibitors to drive tumor regressions and durable responses in KRASG12C-mutant non-small cell lung cancer (NSCLC).

Brand Name : KO-2806

Molecule Type : Small molecule

Upfront Cash : Not Applicable

September 28, 2023

blank

Details:

Cabometyx (Cabozantinib) tablet is a Mmultiple Rreceptor tyrosine kinases inhibitor, which is investigated for the treatment of advanced pancreatic and extra-pancreatic neuroendocrine tumors.


Lead Product(s): Cabozantinib

Therapeutic Area: Oncology Brand Name: Cabometyx

Study Phase: Phase IIIProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 24, 2023

blank

09

Exelixis

U.S.A
arrow
SupplySide West 2024
Not Confirmed

Exelixis

U.S.A
arrow
SupplySide West 2024
Not Confirmed

Details : Cabometyx (Cabozantinib) tablet is a Mmultiple Rreceptor tyrosine kinases inhibitor, which is investigated for the treatment of advanced pancreatic and extra-pancreatic neuroendocrine tumors.

Brand Name : Cabometyx

Molecule Type : Small molecule

Upfront Cash : Not Applicable

August 24, 2023

blank

Details:

Cabometyx (Cabozantinib) tablet is a multiple receptor tyrosine kinases inhibitor, being investigated in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer.


Lead Product(s): Cabozantinib,Atezolizumab

Therapeutic Area: Oncology Brand Name: Cabometyx

Study Phase: Phase IIIProduct Type: Small molecule

Sponsor: Ipsen

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 21, 2023

blank

10

Exelixis

U.S.A
arrow
SupplySide West 2024
Not Confirmed

Exelixis

U.S.A
arrow
SupplySide West 2024
Not Confirmed

Details : Cabometyx (Cabozantinib) tablet is a multiple receptor tyrosine kinases inhibitor, being investigated in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer.

Brand Name : Cabometyx

Molecule Type : Small molecule

Upfront Cash : Not Applicable

August 21, 2023

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDA Orange Book

read-more
read-more

01

SupplySide West 2024
Not Confirmed
arrow
arrow
SupplySide West 2024
Not Confirmed

CABOZANTINIB

Brand Name : CABOZANTINIB

Dosage Form : TABLET;ORAL

Dosage Strength : 20MG

Approval Date :

Application Number : 215942

RX/OTC/DISCN :

RLD :

TE Code :

blank

02

SupplySide West 2024
Not Confirmed
arrow
arrow
SupplySide West 2024
Not Confirmed

CABOZANTINIB

Brand Name : CABOZANTINIB

Dosage Form : TABLET;ORAL

Dosage Strength : 40MG

Approval Date :

Application Number : 215942

RX/OTC/DISCN :

RLD :

TE Code :

blank

03

SupplySide West 2024
Not Confirmed
arrow
arrow
SupplySide West 2024
Not Confirmed

CABOZANTINIB

Brand Name : CABOZANTINIB

Dosage Form : TABLET;ORAL

Dosage Strength : 60MG

Approval Date :

Application Number : 215942

RX/OTC/DISCN :

RLD :

TE Code :

blank

04

EXELIXIS

U.S.A
SupplySide West 2024
Not Confirmed
arrow

EXELIXIS

U.S.A
arrow
SupplySide West 2024
Not Confirmed

CABOZANTINIB S-MALATE

Brand Name : COMETRIQ

Dosage Form : CAPSULE;ORAL

Dosage Strength : EQ 20MG BASE

Approval Date : 2012-11-29

Application Number : 203756

RX/OTC/DISCN : RX

RLD : Yes

TE Code :

blank

05

EXELIXIS

U.S.A
SupplySide West 2024
Not Confirmed
arrow

EXELIXIS

U.S.A
arrow
SupplySide West 2024
Not Confirmed

CABOZANTINIB S-MALATE

Brand Name : COMETRIQ

Dosage Form : CAPSULE;ORAL

Dosage Strength : EQ 80MG BASE

Approval Date : 2012-11-29

Application Number : 203756

RX/OTC/DISCN : RX

RLD : Yes

TE Code :

blank

06

EXELIXIS INC

U.S.A
SupplySide West 2024
Not Confirmed
arrow

EXELIXIS INC

U.S.A
arrow
SupplySide West 2024
Not Confirmed

CABOZANTINIB S-MALATE

Brand Name : CABOMETYX

Dosage Form : TABLET;ORAL

Dosage Strength : EQ 20MG BASE

Approval Date : 2016-04-25

Application Number : 208692

RX/OTC/DISCN : RX

RLD : Yes

TE Code :

blank

07

EXELIXIS INC

U.S.A
SupplySide West 2024
Not Confirmed
arrow

EXELIXIS INC

U.S.A
arrow
SupplySide West 2024
Not Confirmed

CABOZANTINIB S-MALATE

Brand Name : CABOMETYX

Dosage Form : TABLET;ORAL

Dosage Strength : EQ 40MG BASE

Approval Date : 2016-04-25

Application Number : 208692

RX/OTC/DISCN : RX

RLD : Yes

TE Code :

blank

08

EXELIXIS INC

U.S.A
SupplySide West 2024
Not Confirmed
arrow

EXELIXIS INC

U.S.A
arrow
SupplySide West 2024
Not Confirmed

CABOZANTINIB S-MALATE

Brand Name : CABOMETYX

Dosage Form : TABLET;ORAL

Dosage Strength : EQ 60MG BASE

Approval Date : 2016-04-25

Application Number : 208692

RX/OTC/DISCN : RX

RLD : Yes

TE Code :

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Europe

read-more
read-more

01

Ipsen Pharma

France
SupplySide West 2024
Not Confirmed
arrow

Ipsen Pharma

France
arrow
SupplySide West 2024
Not Confirmed

Cabozantinib

Brand Name : Cabometyx

Dosage Form : Antic-calc Tablet, Film Coated

Dosage Strength : 20 mg

Packaging : Bottle

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Norway

blank

02

Ipsen Pharma

France
SupplySide West 2024
Not Confirmed
arrow

Ipsen Pharma

France
arrow
SupplySide West 2024
Not Confirmed

Cabozantinib

Brand Name : Cabometyx

Dosage Form : Antic-calc Tablet, Film Coated

Dosage Strength : 40 mg

Packaging : Bottle

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Norway

blank

03

Ipsen Pharma

France
SupplySide West 2024
Not Confirmed
arrow

Ipsen Pharma

France
arrow
SupplySide West 2024
Not Confirmed

Cabozantinib

Brand Name : Cabometyx

Dosage Form : Antic-calc Tablet, Film Coated

Dosage Strength : 60 mg

Packaging : Bottle

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Norway

blank

04

Ipsen Pharma

France
SupplySide West 2024
Not Confirmed
arrow

Ipsen Pharma

France
arrow
SupplySide West 2024
Not Confirmed

Cabozantinib

Brand Name : Cometriq

Dosage Form :

Dosage Strength :

Packaging : Blister

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Norway

blank

05

Ipsen Pharma

France
SupplySide West 2024
Not Confirmed
arrow

Ipsen Pharma

France
arrow
SupplySide West 2024
Not Confirmed

Cabozantinib

Brand Name : Cometriq

Dosage Form :

Dosage Strength :

Packaging : Blister

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Norway

blank

06

Ipsen Pharma

France
SupplySide West 2024
Not Confirmed
arrow

Ipsen Pharma

France
arrow
SupplySide West 2024
Not Confirmed

Cabozantinib

Brand Name : Cometriq

Dosage Form : Capsule, hard

Dosage Strength : 20 mg

Packaging : Blister

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Norway

blank

07

SupplySide West 2024
Not Confirmed
arrow
arrow
SupplySide West 2024
Not Confirmed

Cabozantinib

Brand Name : Cabometyx

Dosage Form : Film-Coated Tablets

Dosage Strength : 20mg

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Switzerland

blank

08

SupplySide West 2024
Not Confirmed
arrow
arrow
SupplySide West 2024
Not Confirmed

Cabozantinib

Brand Name : Cabometyx

Dosage Form : Film-Coated Tablets

Dosage Strength : 40mg

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Switzerland

blank

09

SupplySide West 2024
Not Confirmed
arrow
arrow
SupplySide West 2024
Not Confirmed

Cabozantinib

Brand Name : Cabometyx

Dosage Form : Film-Coated Tablets

Dosage Strength : 60mg

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Switzerland

blank

10

TMC Pharma Services Ltd.,

Country
SupplySide West 2024
Not Confirmed
arrow

TMC Pharma Services Ltd.,

Country
arrow
SupplySide West 2024
Not Confirmed

kabozantinib S-malate

Brand Name : Cometriq

Dosage Form : HARD CAPSULES

Dosage Strength : 20 MG

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Sweden

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

DRUG PRODUCT COMPOSITIONS

Do you need Business Intel? Ask us

DOSAGE - CAPSULE;ORAL - EQ 20MG BASE

USFDA APPLICATION NUMBER - 203756

read-more

DOSAGE - CAPSULE;ORAL - EQ 80MG BASE

USFDA APPLICATION NUMBER - 203756

read-more

Related Excipient Companies

Upload your portfolio for free, ask us

Excipients by Applications

Click here to find the perfect excipient manufacturers by their capabilities

Coating Systems & Additives

read-more
read-more

Fillers, Diluents & Binders

read-more
read-more

Disintegrants & Superdisintegrants

read-more
read-more

Controlled & Modified Release

read-more
read-more

Direct Compression

read-more
read-more

Thickeners and Stabilizers

read-more
read-more

Lubricants & Glidants

read-more
read-more

Film Formers & Plasticizers

read-more
read-more

Granulation

read-more
read-more

Co-Processed Excipients

read-more
read-more

Empty Capsules

read-more
read-more

Coloring Agents

read-more
read-more

Emulsifying Agents

read-more
read-more

Vegetarian Capsules

read-more
read-more

API Stability Enhancers

read-more
read-more

Taste Masking

read-more
read-more

Topical

read-more
read-more

Solubilizers

read-more
read-more

Rheology Modifiers

read-more
read-more

Chewable & Orodispersible Aids

read-more
read-more

Parenteral

read-more
read-more

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

STOCK RECAP #PipelineProspector

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty